ABSTRACT
Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed whether the risk is increased in patients receiving concomitant valproate therapy in a population of 103 adult patients with intractable epilepsy, who had lamotrigine added to their treatment. Of the 33 patients taking valproate, 10 (30 per cent) developed a rash, whilst of the 70 not taking valproate, only 6 (8 per cent) developed a rash. This suggests a significantly higher risk of cutaneous rash when starting lamotrigine in patients already taking valproate (pSubject(s)
Humans
, Male
, Female
, Adolescent
, Adult
, Middle Aged
, Anticonvulsants/adverse effects
, Drug Eruptions/etiology
, Valproic Acid/administration & dosage
, Valproic Acid/therapeutic use
, Anticonvulsants/administration & dosage
, Triazines/administration & dosage
, Triazines/adverse effects